Introduction
============

Stroke is the second leading cause of death and years of life lost among adults worldwide.[@b1-clep-10-1839] Approximately 5.5 million deaths globally were attributed to stroke in 2016, and the annual cost of stroke was estimated to be \~US\$30,000 per patient worldwide.[@b1-clep-10-1839],[@b2-clep-10-1839] Along with depression, acute myocardial infarction, sleep disorders, pneumonia, gastrointestinal bleeding, urinary tract infection, recurrent stroke, and post-stroke falls, epilepsy is considered a common complication after stroke.[@b3-clep-10-1839]--[@b7-clep-10-1839] The prevalence of epilepsy among stroke patients was estimated to range from 6.3% to 12.4%.^8.9^ After the first seizure, patients may develop recurrent seizures and exhibit increased fatality.[@b10-clep-10-1839]

Traditional Chinese medicine (TCM) is commonly used in Taiwan and other Asian countries.[@b11-clep-10-1839]-[@b13-clep-10-1839] A high rate of TCM use among stroke patients in Taiwan was reported in a previous nationwide study,[@b14-clep-10-1839] and receiving adjuvant TCM therapy may be associated with reduced risk of adverse outcomes after stroke.[@b15-clep-10-1839] One component in TCM is Chinese herbal medicine; Bu Yang Huan Wu Tang (BYHWT) is commonly prescribed Chinese herbal formula for stroke patients in Taiwan.[@b16-clep-10-1839],[@b17-clep-10-1839] Experimental studies have indicated that BYHWT has neuroprotective and neurogenesis-promoting effects in rats with cerebral ischemia.[@b18-clep-10-1839]--[@b21-clep-10-1839] Huanqi is one of the components of BYHWT that was suggested as a potent prescription for the treatment of endothelium-related vascular complications.[@b49-clep-10-1839] However, limited information is available regarding whether BYHWT has beneficial antiepileptic effects in stroke patients.

Using insurance-based data from Taiwan, we conducted a nationwide retrospective cohort study with matching by propensity score to investigate the risk of epilepsy in stroke patients who received BYHWT and those who did not.

Methods
=======

Source of data
--------------

More than 99% of Taiwan's 23 million residents are covered by Taiwan's National Health Insurance Program, which has been in place since March 1995 (insurance claims data are available since 1996). Our research data were obtained from the reimbursement claims of Taiwan's National Health Insurance. The details of this database were described in our previous studies.[@b7-clep-10-1839],[@b23-clep-10-1839] The validity of the current database has been adequately evaluated,[@b41-clep-10-1839]--[@b43-clep-10-1839] and research articles based on it have been published in prominent scientific journals worldwide.[@b44-clep-10-1839]--[@b47-clep-10-1839]

Ethical approval
----------------

Our research data were released for academic research access by Taiwan's National Health Insurance Research Database and Data Science Center, Ministry of Health and Welfare, and informed consent was not required because personal privacy was protected by using decoding and scrambling patients' identification. After critical evaluation, our study was approved by the Institutional Review Board of E-DA Hospital (EDA-JIRB-EMRP105144).

Study design
------------

Among the 23 million residents of Taiwan, we identified \>200,000 new stroke survivors aged ≥20 years who were admitted to the hospital (people who received inpatient care with a physician's primary diagnosis of stroke) between January 1, 2000 and December 31, 2004. To confirm that all stroke patients in our study were incident cases, we included only new-onset stroke cases in the analysis, and those with a previous recorded stroke history within 4 years before the index date were excluded. In addition, new-onset stroke patients who had a history of epilepsy were excluded from this study. Among 96,131 eligible stroke survivors, 15,936 had received BYHWT at TCM clinics during the follow-up period after being admitted to hospital for stroke.

To avoid misclassification, we used a propensity score matching procedure (exposure vs non-exposure ratio=1:1) to selected a non-BYHWT control group of stroke patients who did not receive TCM therapy. In the non-BYHWT control group, stroke patients were followed up from the discharge date of index stroke admission until December 31, 2009 or until the occurrence of an epileptic event, loss to follow-up, or death. To avoid immortal time bias (which might result in overestimation of the intervention's beneficial effects) in the BYHWT group, we followed up the stroke patients from the first date when they received BYHWT after index stroke admission until December 31, 2009 or until an epilepsy event, loss to follow-up, or death. The follow-up time, in person-years, was calculated for each stroke patient from the index date to the end point. We compared the risk of incident epilepsy during the follow-up period between those stroke patients who received BYHWT treatment and those who did not. After matching by propensity score, there were 8,971 pairs of stroke patients with and without BYHWT treatment.

Criteria and definitions
------------------------

The formula BYHWT includes seven Chinese herbs: Huanqi (Radix Astragali seu Hedysari), Danggui (Radix *Angelica sinensis*), Chuanxiong (Rhizoma Ligustici Chuanxiong), Honghua (Flos Carthami), Dilong (Pheretima), Chishao (Radix Paeoniae Rubra), and Taoren (Semen Persicae). The BYHWT prescription in the clinical settings in Taiwan is concentrated Chinese herbal medicine which showed power type. The official recommendation for dosage is three times per day (2.5 g per time), and the treatment duration is at least 6 days. TCM physicians consider every patient's symptoms and complaints and prescribe adequate treatment dosage and duration of BYHWT. According to the regulations of the National Health Insurance system, patients of low-income status were defined as patients who were qualified to waive co-payments for their medical expenditures. We calculated the population density (persons/km^2^) of each administrative unit in Taiwan. Based on population density, these units were stratified into tertiles to designate areas of low, moderate, and high urbanization. We defined newly diagnosed stroke according to the International Classification of Diseases, Ninth Revision, Clinical Modification, as ICD-9-CM 430--437, a definition that has been validated in previous studies.[@b15-clep-10-1839] The primary outcome, namely, the incidence of epilepsy, was defined as patients who sought medical care with a physician's primary diagnosis of epilepsy (ICD-9-CM 345). The ICD-9-CM was also used to identify coexisting medical conditions from medical claims for the follow-up period; these conditions included hypertension (ICD-9-CM 401--405), diabetes (ICD-9-CM 250), mental disorders (290--319), COPD (ICD-9-CM 491, 492, 496), ischemic heart disease (ICD-9-CM 410--414), urinary tract infection (ICD-9-CM 599.0), hyperlipidemia (ICD-9-CM 272.0--272.4), pneumonia (ICD-9-CM 480--486), heart failure (ICD-9-CM 428), epilepsy (ICD-9-CM 345), and liver cirrhosis (ICD-9-CM 571). Renal dialysis was defined by the administration codes D8 and D9. Subtype of stroke (hemorrhage, occlusion and stenosis, transient ischemic attack, and others), use of antiepileptic drugs, whether the patient stayed in a medical center or not, length of hospital stay, admission to the intensive care unit, and receipt of neurosurgery were taken into consideration as baseline covariates between stroke patients with and without BYHWT.

Statistical analysis
--------------------

We used a propensity score-matched pair design combined with frequency matching to balance the covariates (including age, sex, stroke subtype, low income, urbanization, admission to the intensive care unit, neurosurgery, length of hospital stay, subtypes of stroke, rehabilitation during follow-up, antiepileptic drugs, hypertension, diabetes, hyperlipidemia, mental disorders, cancer, head injuries, Parkinson's disease, renal dialysis, and Alzheimer's disease) between the BYHWT group and the non-BYHWT group. For achieving a balance of covariates within matched pairs, we performed a structured iterative approach to refine this logistic regression model using 1:1 case--control match on the propensity score. We then matched (without replacement) patients who had BYHWT with those who did not by using a greedy matching algorithm. The algorithm proceeds sequentially to the lowest digit match on propensity score (one digit). This will be referred to as the 8--1 digit match.

The frequency distributions of baseline characteristics were compared by chi-squared tests and Student's *t*-tests. We used multiple Cox proportional hazard regression models to calculate the adjusted HRs and 95% CIs for epilepsy in stroke patients during the follow-up period according to BYHWT use. The association between BYHWT and post-stroke epilepsy in the subgroup analysis was also analyzed in the multiple Cox proportional hazard regression models. Additionally, the joint effects of acupuncture and BYHWT were estimated in further analysis by calculating adjusted HRs (95% CIs).

Results
=======

Due to the propensity score matching procedure, no significant differences in sex, age, low income, intensive care, neurosurgery, rehabilitation in follow-up, subtype of stroke, coexisting medical condition, antiepileptic drug, or length of hospital stay were noted between stroke patients who used BYHWT and those who did not ([Table 1](#t1-clep-10-1839){ref-type="table"}). Among the stroke patients who used BYHWT, 62.3% were males and 56.1% were older people aged ≥65 years. There were 70.8% stroke patients with ischemia (occlusion and stenosis) and most of them had hypertension (91.7%).

During the follow-up period ([Figure 1](#f1-clep-10-1839){ref-type="fig"}), the probability of epilepsy in patients receiving BYHWT was reduced compared to that in patients not receiving TCM. Among 17,942 stroke patients, 1,222 epilepsy events occurred during the follow-up period and 474 epilepsy events occurred in stroke patients receiving BYHWT ([Table 2](#t2-clep-10-1839){ref-type="table"}). The incidences of epilepsy in stroke patients with and without use of BYHWT were 11.6 and 16.1 per 1,000 person-years, respectively. After adjustment for all covariates listed in [Table 1](#t1-clep-10-1839){ref-type="table"}, stroke patients receiving BYHWT had a decreased risk of epilepsy (HR 0.69, 95% CI 0.61--0.77) compared with those who did not receive BYHWT. The association between receiving BYHWT and reduced risk of post-stroke epilepsy was significant in women (HR 0.57, 95% CI 0.47--0.70), men (HR 0.76, 95% CI 0.66--0.87), and stroke patients aged 20--74 years, as well as in individuals who had experienced hemorrhagic stroke (HR 0.69, 95% CI 0.50--0.96), occlusion or stenosis (HR 0.71, 95% CI 0.62--0.82), transient ischemic attack (HR 0.41, 95% CI 0.24--0.72), and other stroke types (HR 0.64, 95% CI 0.46--0.90). The use of BYHWT was also associated with reduced post-stroke epilepsy in patients regardless of the length of their hospital stay (1--3, 4--6, 7--9, or ≥10 days), the number of medical conditions they had during follow-up (0, 1, 2, or ≥3), whether they stayed in an intensive care unit or not, and whether they attended rehabilitation or not. The subgroup showed that patients with transient ischemic attack had a very low incidence of epilepsy (5.5 per 1,000 person-years in BYHWT group and 12.4 per 1,000 person-years in the group without BYHWT) with an adjusted HR of 0.41 (95% CI 0.24--0.72) associated with BYHWT use.

Among stroke patients, the risk of epilepsy showed a dose-dependent decrease as the quantity of BYHWT use increased ([Table 3](#t3-clep-10-1839){ref-type="table"}), from 1 package (HR 0.77, 95% CI 0.66--0.90) to ≥6 packages (HR 0.52, 95% CI 0.42--0.65).

Compared to the non-BYHWT control group, stroke patients receiving BYHWT only (HR 0.69, 95% CI, 0.58--0.83) or receiving BYHWT and acupuncture (HR 0.68, 95% CI 0.60--0.78) exhibited a reduced incidence and risk of epilepsy ([Table 4](#t4-clep-10-1839){ref-type="table"}).

The association between days of BYHWT treatment and reduced risk of post-stroke epilepsy was significant when the decoction was taken for \>6 days ([Table S1](#SD1-clep-10-1839){ref-type="supplementary-material"}). The top formula and herbal medicine prescribed to accompany BYHWT were Tianma Gouteng Decoction and Dan Shen, respectively ([Table S2](#SD2-clep-10-1839){ref-type="supplementary-material"}). The top ten formulas and the top ten herbs prescribed to stroke patients in combination with BYHWT during the follow-up period are shown in [Table S3](#SD3-clep-10-1839){ref-type="supplementary-material"}.

Discussion
==========

To our knowledge, the present study is the first to use nationwide data, propensity score matching, and a retrospective cohort study design to report a significant association between use of BYHWT and reduced risk of post-stroke epilepsy, and this beneficial effect could be observed in various subgroups of stroke patients. Further analysis also revealed a graded biological relationship between the number of packages of BYHWT used and the risk of post-stroke epilepsy.

Age, sex, low income, hypertension, hyperlipidemia, diabetes mellitus, and mental disorder were the factors associated with stroke.[@b24-clep-10-1839] These sociodemographic factors and medical conditions are also associated with epilepsy.[@b25-clep-10-1839] In addition, neurosurgery, intensive care, and length of hospital stay also impact the incidence of post-stroke epilepsy.[@b26-clep-10-1839] To reduce the confounding effects of these stroke-related and epilepsy-related factors, we used a matching procedure with propensity scores to control these potential confounders.

Our stratification analysis revealed that the association between BYHWT treatment and reduced risk of post-stroke epilepsy remained significant in 20- to 74-year-old stroke patients, both sexes, and every stroke subtype, regardless of the number of other medical conditions present. In addition, stroke patients who received BYHWT either alone or in combination with acupuncture had a significantly decreased risk of epilepsy. Despite the suboptimal sensitivity of this study, our findings still provide grounds for a possible relationship between BYHWT treatment and reduced risk of post-stroke epilepsy from the viewpoint of epidemiology.

In a rat model of ischemia-reperfusion injury, BYHWT treatment improved the nerve function, and the beneficial effects greatly increased as the dose of BYHWT increased.[@b27-clep-10-1839] A similar dose--response relationship was also observed in our study: the incidence of post-stroke epilepsy decreased as the dose of BYHWT increased, and patients who used the treatment for \>36 days had a lower risk of post-stroke epilepsy than those who used it for 5 or fewer days. However, well-designed prospective studies or clinical trials will be necessary to provide solid evidence for the graded, beneficial biological effects of BYHWT.

BYHWT is used to treat a variety of diseases, including stroke, vertigo, vascular dementia, coronary heart disease, and chemotherapy-induced neuropathy.[@b28-clep-10-1839],[@b29-clep-10-1839] A systematic review suggested that BYHWT is generally safe and can improve neurological deficits for acute ischemic stroke patients.[@b22-clep-10-1839] However, previous results have been insufficient to support the routine use of BYHWT for acute stroke due to the poor methodological quality of the studies.[@b22-clep-10-1839] Departing from the existing literature, we conducted a nationwide study with a large sample size, propensity score matching, immortal time adjustment, and multivariate Cox proportional hazard models. Our study, with its improved methodological quality, raised the possibility that BYHWT may be beneficial in reducing the risk of epilepsy in stroke patients.

Although post-stroke hypoxia, metabolic dysfunction, inflammatory responses, and blood--brain barrier damage were identified as factors associated with post-stroke epilepsy,[@b5-clep-10-1839],[@b30-clep-10-1839] epileptogenesis itself is still quite a poorly known phenomenon. A previous study suggested that BYHWT may restore the brain function and improve neurological deficits in a mouse model of ischemic stroke.[@b31-clep-10-1839] In the same study, BYHWT also reduced inflammation, oxidative stress, and apoptosis, in addition to improving neurogenesis.[@b31-clep-10-1839]

In general, BYHWT includes seven Chinese herbs, and the effects of its active components have been widely reported as follows. The major herb of BYHWT is Huanqi, which is beneficial for patients with post-stroke fatigue and improves the functional outcomes of hemorrhagic stroke patients.[@b32-clep-10-1839],[@b33-clep-10-1839] The major active component of Huanqi is astragaloside IV that has neuroprotective properties stemming from antioxidative, antiapoptotic, and anti-inflammatory actions.[@b34-clep-10-1839],[@b35-clep-10-1839] Tetramethylpyrazine, found in Chuanxiong, has been shown to have anti-inflammatory and neuroprotective effects in an experimental study.[@b36-clep-10-1839] Ferulic acid, found in Danggui and Chuanxiong, has anti-oxidative properties that provide neuroprotective effects.[@b37-clep-10-1839] Hydroxysafflor yellow A, found in Honghua, provides neuroprotection against cerebral injury by modulating inflammatory and apoptotic processes.[@b38-clep-10-1839] In addition, Dilong, Chishao, and Taoren have beneficial effects on cerebral ischemic injury.[@b39-clep-10-1839] The above experimental evidence provides possible explanations for the beneficial neuroprotective effects of BYHWT in stroke patients. Possible therapeutic effects of the components of BYHWT are listed in [Table S4](#SD4-clep-10-1839){ref-type="supplementary-material"}.

However, there is still lack of reports on the molecules and pathways involved in the mechanisms of BYHWT. It may not be safe and scientifically sound to promote some therapies without clear safety data and mechanisms. We seriously suggest that people using BYHWT should fully comply with professional physician's directions. Further repeatable, randomized, double-blinded experiments will be necessary to establish solid evidence of the benefits of BYHWT and characterize its mechanisms in humans.

Limitations
===========

First, we used insurance claims data, which lack information on the clinical risk scores (such as the National Institute of Health Stroke Scale or the Barthel index), lesion characteristics (location and size), biochemical measures (such as glucose, total cholesterol, and high-sensitivity C-reactive protein), and patients' lifestyle (such as smoking, alcohol drinking, and physical activity). Cortical stroke location is also an important risk factor for post-stroke epilepsy, but our study was limited by the unavailable information on this.[@b48-clep-10-1839] Second, although the diagnosis codes of diseases and medications are validated to be accurate,[@b40-clep-10-1839] patients with mild symptoms of epilepsy may simply not seek medical care. Third, out-of-pocket purchases of Chinese herbal remedies and over-the-counter herbal medicines could not be evaluated because we used only the claims data of the National Health Insurance. Fourth, physician's prescription is not equal to patient's intake. The use of BYHWT in this study is physician's prescription, which may not reflect the actual use of the medication in stroke patients. Fifth, those who take the medications as directed may also be more likely to do more to improve their health and recovery. The beneficial effects in reducing epilepsy among stroke patients in this study are not all derived from BYHWT. Fifth, we could not exclude the possibility of selection bias because the control group (stroke patients without using BYHWT) was selected by the baseline characteristics of the treatment group (stroke patients using BYHWT) with matching procedure by propensity score. In addition, the doses of BYHWT and other combined Chinese herbal remedies for patients with stroke varied across TCM physicians. We could not exclude the potential therapeutic effects of other prescribed Chinese herbal medicines in stroke patients. The possible side effects or adverse effects of the components of BYHWT should also not be ignored in this study ([Table S5](#SD5-clep-10-1839){ref-type="supplementary-material"}). Finally, residual confounding may exist in our study, despite the comprehensive matching and multiple regression adjustment. The severity of stroke (stroke-related comorbidities, clinical risk scores, lesion characteristics, and cortical stroke location) is an important confounding factor that was not considered in our study, and several potential confounders (detailed medication use, biochemical measures, lifestyles, socioeconomic status, genetics, family history, and use of other folk therapies) were not matched or adjusted in our analysis. All the positive effects of BYHWT in stroke patients in this study might not be due to BYHWT itself. Better lifestyle habits and using other conventional treatment (Western medicine) also contribute to reducing post-stroke epilepsy.

Conclusion
==========

Our study suggests that stroke patients receiving BYHWT treatment exhibited a reduced risk of post-stroke epilepsy compared to patients who did not receive BYHWT, and this association could be observed in various subgroups. However, well-designed, high-quality randomized controlled trials are needed to confirm the beneficial effect of BYHWT on the risk of post-stroke epilepsy.

Supplementary materials
=======================

###### 

Comparison of baseline characteristics between stroke patients with and without Bu Yang Huan Wu Tang before matching procedure

                                 Bu Yang Huan Wu Tang   Absolute difference (%)   
  ------------------------------ ---------------------- ------------------------- -------
  Sex                            n (%)                  n (%)                     
   Female                        33,429 (41.7)          6,373 (40.0)              4.08
   Male                          46,766 (58.3)          9,563 (60.0)              2.83
  Age, years                                                                      
   20--44                        2,407 (3.0)            1,057 (6.6)               54.55
   45--54                        6,650 (8.3)            3,021 (19.0)              56.32
   55--64                        12,541 (15.6)          4,463 (28.0)              44.29
   65--74                        25,913 (32.3)          5,111 (32.1)              0.31
   ≥75                           32,684 (40.8)          2,284 (14.3)              64.95
  Low income                     4,339 (5.4)            823 (5.2)                 3.70
  Intensive care unit stay       11,841 (14.8)          2,423 (15.2)              2.63
  Neurosurgery                   2,505 (3.1)            506 (3.2)                 3.13
  Length of stay, days                                                            1.00
   1--3                          1,685 (18.8)           1,685 (18.8)              
   4--6                          2,875 (32.1)           2,875 (32.1)              
   7--9                          1,880 (21.0)           1,880 (21.0)              
   ≥10                           2,531 (28.2)           2,531 (28.2)              
  Mean±SD                        8.91±6.90              8.97±6.75                 0.67
  Subtypes of stroke                                                              
   Hemorrhage                    8,800 (11.0)           2,564 (16.1)              31.68
   Occlusion and stenosis        47,247 (58.9)          9,712 (60.9)              3.28
   Transient ischemic attack     10,940 (13.6)          1,431 (9.0)               33.82
   Others                        13,208 (16.5)          2,229 (14.0)              15.15
  Intensive rehabilitation       29,618 (36.9)          9,546 (59.9)              38.40
  Basic rehabilitation           27,597 (34.4)          8,671 (54.4)              36.76
  Antiepileptic drug             21,975 (27.4)          6,010 (37.7)              27.32
  Coexisting medical condition                                                    
   Hypertension                  60,364 (75.3)          14,094 (88.4)             14.82
   Diabetes                      30,935 (38.6)          6,913 (43.4)              11.09
   Hyperlipidemia                20,272 (25.3)          7,488 (47.0)              46.17
   Mental disorder               24,317 (30.3)          6,591 (41.4)              26.81
   Cancer                        9,388 (11.7)           1,815 (11.4)              2.56
   Head injury                   8,401 (10.5)           2,175 (13.7)              23.36
   Parkinson's disease           4,201 (5.2)            995 (6.2)                 16.13
   Renal dialysis                3,313 (4.1)            413 (2.6)                 36.59
   Alzheimer's disease           512 (0.6)              69 (0.4)                  33.33

###### 

Risk of post-stroke epilepsy during the follow-up period treatment days of BYHWT

  BYHWT                        n       Events   Person-years   Incidence   HR (95% CI)[\*](#tfn8-clep-10-1839){ref-type="table-fn"}
  ---------------------------- ------- -------- -------------- ----------- ----------------------------------------------------------
  No BYHWT                     8,971   748      46,455         16.1        1.00 (reference)
  Cumulative treatment, days                                               
   1--7                        3,382   189      14,402         13.1        0.77 (0.65--0.90)
   8--14                       1,520   92       6,871          13.4        0.79 (0.64--0.98)
   15--21                      870     45       4,143          10.9        0.65 (0.48--0.88)
   22--25                      536     28       2,524          11.1        0.66 (0.45--0.97)
   29--35                      429     21       2,019          10.5        0.62 (0.40--0.96)
   36--42                      340     18       1,557          11.6        0.68 (0.43--1.09)
   43--49                      222     6        1,068          5.6         0.34 (0.15--0.75)
   ≥50                         1,672   75       8,428          8.9         0.54 (0.42--0.68)

**Note:**

Adjusted for all covariates listed in [Table 1](#t1-clep-10-1839){ref-type="table"}.

**Abbreviation:** BYHWT, Bu Yang Huan Wu Tang.

###### 

The top ten formulas and the top ten herbs prescribed to stroke patients in combination with Bu Yang Huan Wu Tang during the follow-up period

  Herbs         Frequency   \%     Formulas                     Frequency   \%
  ------------- ----------- ------ ---------------------------- ----------- ------
  Dan Shen      56,629      4.97   Tian Ma Gou Teng Yin         27,907      3.67
  San Qi        26,521      2.33   Ma Zi Ren Wan                21,751      2.86
  Du Zhong      22,997      2.02   Xue Fu Zhu Yu Tang           21,728      2.86
  Da Huang      21,248      1.86   Shu Jing Huo Xie Tang        19,747      2.60
  Niu Xi        21,033      1.85   Du Huo Ji Sheng Tang (Wan)   16,070      2.11
  Tian Ma       19,477      1.71   Ji Sheng Shen Qi Wan         15,215      2.00
  Huang Qi      18,148      1.59   Sheng Mai San                14,980      1.97
  Ge Gen        18,106      1.59   Liu Wei Di Huang San (Wan)   14,501      1.91
  Xu Duan       14,437      1.27   Zhi Gan Cao Tang             13,542      1.78
  Ji Xue Teng   14,310      1.26   Qi Ju Di Huang Wan           11,794      1.55

###### 

Possible therapeutic effects of components of Bu Yang Huan Wu Tang

  English name                                     Official name                Possible therapeutic effects
  ------------------------------------------------ ---------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                
  Huanqi[@b50-clep-10-1839],[@b51-clep-10-1839]    Astragali Radix              Enhances immunity, inhibits the formation of lipid peroxides in the myocardium, decreases blood coagulation, has increased efficacy against vesicular stomatitis
  Danggui[@b52-clep-10-1839],[@b53-clep-10-1839]   Radix *Angelicae Sinensis*   Improves dysmenorrhea and irregular menstruation, shows anti-inflammatory activity
  Chishao[@b54-clep-10-1839]                       Paeoniae Rubra Radix         Reduces fevers, induces sterility, and treats burns
  Dilong[@b55-clep-10-1839]                        Pheretima                    Improves delirium (due to high fever), headache, acute conjunctivitis, hemiplegia
  Chuanxiong[@b56-clep-10-1839]                    Chuanxiong Rhizoma           Anti-cerebral ischemia activity, anti-myocardial ischemia activity, protects vascular function, antithrombotic activity, antihypertensive, anti-atherosclerotic, anti-inflammatory activity, anticancer activity, antioxidant activity, liver protection
  Taoren[@b57-clep-10-1839],[@b58-clep-10-1839]    Persicae Semen               Anticoagulant, promotes blood circulation, removes blood stasis, relieves constipation, removes blood stasis
  Honghua[@b58-clep-10-1839]                       Carthami Flos                Improves blood circulation, stimulates menstrual discharge, removes blood stasis, relieves pain

###### 

Possible side/adverse effects of components of Bu Yang Huan Wu Tang

  English name                                         Official name                Possible adverse effects
  ---------------------------------------------------- ---------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                    
  Huanqi[@b59-clep-10-1839]                            Astragali Radix              Diarrhea, mild gastrointestinal effects, may affect blood sugar levels and blood pressure
  Danggui[@b60-clep-10-1839]                           Radix *Angelicae Sinensis*   Abdominal pain, amenorrhea, diarrhea, dystonia, gastrointestinal hemorrhage, hematemesis, irregular menstruation, nausea, edema peripheral, pruritus, rash, somnolence, tongue spasm, urticaria, vaginal hemorrhage
  Chishao[@b61-clep-10-1839]                           Paeoniae Rubra Radix         Blistering of mouth and throat, diarrhea, dizziness, fainting, gastroenteritis, hematuria, nausea, salivation, stomach pain, vomiting
  Dilong[@b62-clep-10-1839]                            Pheretima                    Dizziness, fever, perspiration, photophobia, tearing, rummy nose, excess salivation, nausea
  Chuanxiong[@b63-clep-10-1839]--[@b65-clep-10-1839]   Chuanxiong Rhizoma           Allergic reaction, vomiting, vertigo, nausea
  Taoren[@b66-clep-10-1839]                            Persicae Semen               Nausea, vomiting, irritation of the gastrointestinal tract, headache, dizziness, weakness, blurred vision, increased heart rate, incontinence of the urine or stool, dilation of pupils
  Honghua[@b66-clep-10-1839],[@b67-clep-10-1839]       Carthami Flos                Bleeding, nausea, headache, dilated, pupils, increase in intraocular pressure, anaphylactic reaction
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![The estimated epilepsy probability of stroke patients with and without Bu Yang Huan Wu Tang using the Kaplan--Meier method (log-rank test, *P*\<0.0001).](clep-10-1839Fig1){#f1-clep-10-1839}

###### 

Comparison of the baseline characteristics between stroke patients with and without Bu Yang Huan Wu Tang

                                 Bu Yang Huan Wu Tang   Absolute difference (%)   
  ------------------------------ ---------------------- ------------------------- ------
  Sex                            n (%)                  n (%)                     1.00
   Female                        3,382 (37.7)           3,382 (37.7)              
   Male                          5,589 (62.3)           5,589 (62.3)              
  Age, years                                                                      1.00
   20--44                        289 (3.2)              289 (3.2)                 
   45--54                        1,232 (13.7)           1,232 (13.7)              
   55--64                        2,427 (27.1)           2,427 (27.1)              
   65--74                        3,431 (38.3)           3,431 (38.3)              
   ≥75                           1,592 (17.8)           1,592 (17.8)              
  Low income                     121 (1.4)              121 (1.4)                 1.00
  Intensive care unit stay       714 (8.0)              714 (8.0)                 1.00
  Neurosurgery                   119 (1.3)              119 (1.3)                 1.00
  Length of stay, days                                                            1.00
   1--3                          1,685 (18.8)           1,685 (18.8)              
   4--6                          2,875 (32.1)           2,875 (32.1)              
   7--9                          1,880 (21.0)           1,880 (21.0)              
   ≥10                           2,531 (28.2)           2,531 (28.2)              
  Mean±SD                        8.06±5.89              8.07±5.93                 0.12
  Subtypes of stroke                                                              1.00
   Hemorrhage                    780 (8.7)              780 (8.7)                 
   Occlusion and stenosis        6,348 (70.8)           6,348 (70.8)              
   Transient ischemic attack     743 (8.3)              743 (8.3)                 
   Others                        1,100 (12.3)           1,100 (12.3)              
  Intensive rehabilitation       4,886 (54.5)           4,886 (54.5)              1.00
  Basic rehabilitation           4,344 (48.4)           4,344 (48.4)              
  Antiepileptic drug             2,589 (28.9)           2,589 (28.9)              1.00
  Coexisting medical condition                                                    
   Hypertension                  8,226 (91.7)           8,226 (91.7)              1.00
   Diabetes                      3,858 (43.0)           3,858 (43.0)              1.00
   Hyperlipidemia                3,734 (41.6)           3,734 (41.6)              1.00
   Mental disorder               2,978 (33.2)           2,978 (33.2)              1.00
   Cancer                        643 (7.2)              643 (7.2)                 1.00
   Head injury                   557 (6.2)              557 (6.2)                 1.00
   Parkinson's disease           235 (2.6)              235 (2.6)                 1.00
   Renal dialysis                108 (1.2)              108 (1.2)                 1.00
   Alzheimer's disease           6 (0.1)                6 (0.1)                   1.00

###### 

Epilepsy risk and subgroup analyses between stroke patients with and without BYHWT

                         No BYHWT (n=8,971)   BYHWT (n=8,971)   HR (95% CI)[b](#tfn2-clep-10-1839){ref-type="table-fn"}                         
  ---------------------- -------------------- ----------------- --------------------------------------------------------- ----- -------- ------ -------------------
  All                    748                  46,455            16.1                                                      474   41,013   11.6   0.69 (0.61--0.77)
  Female                 286                  17,632            16.2                                                      149   15,503   9.6    0.57 (0.47--0.70)
  Male                   462                  28,823            16.0                                                      325   25,510   12.7   0.76 (0.66--0.87)
  Age, years                                                                                                                                    
   20--44                31                   1,618             19.2                                                      20    1,364    14.7   0.68 (0.38--1.18)
   45--54                96                   7,277             13.2                                                      62    5,933    10.5   0.72 (0.52--0.99)
   55--64                203                  13,571            15.0                                                      104   11,503   9.0    0.57 (0.45--0.73)
   65--74                292                  17,332            16.8                                                      194   15,943   12.2   0.70 (0.58--0.84)
   ≥75                   126                  6,657             18.9                                                      94    6,271    15.0   0.78 (0.60--1.02)
  No rehabilitation      252                  16,539            15.2                                                      150   14,331   10.5   0.64 (0.52--0.78)
  Rehabilitation         496                  29,917            16.6                                                      324   26,681   12.1   0.71 (0.62--0.81)
  Medical conditions                                                                                                                            
   0                     66                   778               84.8                                                      36    1,088    33.1   0.43 (0.29--0.64)
   1                     221                  8,621             25.6                                                      158   8,462    18.7   0.70 (0.57--0.86)
   2                     262                  15,907            16.5                                                      146   14,241   10.3   0.60 (0.49--0.73)
   ≥3                    199                  21,149            9.4                                                       134   17,222   7.8    0.83 (0.66--1.03)
  Length of stay, days                                                                                                                          
   1--3                  121                  9,113             13.3                                                      75    7,571    9.9    0.69 (0.52--0.92)
   4--6                  236                  15,418            15.3                                                      137   13,079   10.5   0.66 (0.53--0.81)
   7--9                  125                  9,994             12.5                                                      79    8,758    9.0    0.68 (0.51--0.90)
   ≥10                   266                  11,931            22.3                                                      183   11,604   15.8   0.69 (0.58--0.84)
  Subtypes of stroke                                                                                                                            
   Hemorrhage            92                   4,067             22.6                                                      61    3,726    16.4   0.69 (0.50--0.96)
   Occlusion/stenosis    512                  32,523            15.7                                                      342   29,262   11.7   0.71 (0.62--0.82)
   TIA                   52                   4,179             12.4                                                      17    3,113    5.5    0.41 (0.24--0.72)
   Others                92                   5,687             16.2                                                      54    4,913    11.0   0.64 (0.46--0.90)
  ICU stay               100                  3,326             30.1                                                      64    3,319    19.3   0.63 (0.46--0.86)
  No ICU stay            648                  43,129            15.0                                                      410   34,694   10.9   0.69 (0.61--0.78)

**Notes:**

Per 1,000 person-years.

Calculated by univariate Cox proportional hazard model.

**Abbreviations:** BYHWT, Bu Yang Huan Wu Tang; ICU, intensive care unit; IR, incidence rate; PY, person-year; TIA, transient ischemic attack.

###### 

Risk of epilepsy in stroke patients during the follow-up period by the number of packages of Bu Yang Huan Wu Tang

  Number of packages   n       Events   Person-year   Incidence   HR (95% CI)[a](#tfn4-clep-10-1839){ref-type="table-fn"}
  -------------------- ------- -------- ------------- ----------- ---------------------------------------------------------
  0                    8,971   748      46,455        16.1        1.00 (reference)
  1                    3,603   202      15,321        13.2        0.77 (0.66--0.90)
  2                    1,538   93       6,869         13.5        0.80 (0.64--0.99)
  3                    856     48       4,110         11.7        0.70 (0.52--0.94)
  4                    544     28       2,601         10.8        0.65 (0.44--0.94)
  5                    417     16       1,978         8.1         0.48 (0.29--0.79)
  ≥6                   2,013   87       10,134        8.6         0.52 (0.42--0.65)

**Note:**

Calculated by univariate Cox proportional hazard model.

###### 

The joint effects of BYHWT and acupuncture treatment on the risk of epilepsy in stroke patients during the follow-up period

  Treatment combination   n       Cases   Incidence[a](#tfn5-clep-10-1839){ref-type="table-fn"}   HR (95% CI)[b](#tfn6-clep-10-1839){ref-type="table-fn"}
  ----------------------- ------- ------- ------------------------------------------------------- ---------------------------------------------------------
  No BYHWT                8,971   748     16.1                                                    1.00 (reference)
  BYHWT only              2,938   149     11.9                                                    0.69 (0.58--0.83)
  BYHWT and acupuncture   6,033   325     11.4                                                    0.68 (0.60--0.78)

**Notes:**

Per 1,000 person-years.

Calculated by univariate Cox proportional hazard model.

**Abbreviation:** BYHWT, Bu Yang Huan Wu Tang.

[^1]: These authors contributed equally to this work
